
Monday, April 01, 2024 2:00:59 PM
This independent wear study was conducted in accordance with international standards at the Medical Technology Laboratory of the Rizzoli Orthopaedic Institute (Bologna, Italy) by Professor Aldo Toni MD under the supervision of Dr. Saverio Affatato PhD (Rizzoli Institute) with consultation and support from Professor Giuseppe Pezzotti PhD (Ceramic Physics Laboratory, Kyoto Institute of Technology, Sakyo-ku, Kyoto Japan). Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research.
The press release disclosing this was in February 2017. In the following months, Q2 of 2017, Zimmer Biomet paid a 2.5m payment for Certain R&D related expenses. For the longest time i thought the payment was a milestone payment for IP connected to the above testing. However Certain R&D payments are issued for acquiring IP for research purposes that will not be used for products in the future. Given Dr Pezzottis relationship with Zimmer Biomet id hedge to guess that Zimmer paid his research department. Only an investigation of the money trail will tell us for certain, but we know where the money likely ended up, as shown below.
Certain R&D agreements relate to agreements with upfront payments to obtain intellectual property to be used in R&D projects that have no alternative future use in other projects.

My theory is simple, this 2.5m was paid for IP related to the testing that was disclosed in the February 2017 press release. The main issue ive ran into is that i do not know who Zimmer Biomet paid the 2.5m to. It certainly was not Sintx. This part is speculation but if something easily found out by those with the proper resources. It could have been paid to Dr. Pezzotti's research lab, Kyoto Institute itself where Dr Pezzotti works, or even University of Missouri where Dr Bal conducts his testing of Si3n4 based products for Sintx as he also has done work for Zimmer in the past. However the funds were not paid to Dr Bal as this was not disclosed. There would have had to be a middleman if the 2.5m paid by Zimmer Biomet was used by Dr. Bals investment company to loan to Sintx.
July 2017, Dr Bal, through his investment company, loaned Sintx the same amount, 2.5m for 10% interest. As the loan was done through Dr Bals investment company the 2.5m could have been from others than himself. As to which PERSON (individual or business entity) that received the 2.5m from Zimmer Biomet that may have used those funds to loan to Sintx via Dr Bal's investment company, i do not know for certain?
On July 28, 2017, Amedica Corporation (“Amedica” or the “Company”) closed on a $2.5 million term loan (the Loan”) with North Stadium Investments, LLC (“North Stadium”), a company owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board, Dr. Sonny Bal. In connection with the Loan, the Company issued to North Stadium, a Secured Promissory Note in the amount of $2.5 million (the “Note”). The Note bears interest at the rate of 10% per annum, requires the Company to make monthly interest only payments for a period of 12 months, and principal and any unpaid accrued interest are due and payable 12 months from the effective date of the Note, July 28, 2017. The Note is secured by substantially all of the assets of the Company pursuant to a security agreement between the Company and North Stadium dated July 28, 2017 (the “Security Agreement”), and is junior to the already existing security interest in such assets of the Company held by Hercules Capital, Inc. In connection with the Loan and as additional consideration for the Loan, the Company issued to North Stadium a warrant to acquire up to 660,000 common shares with a purchase price set at $0.42 per share and a 5 year term (the “Warrant”).
What the evidence suggests to me is that Zimmer Biomet paid an entity connected with this research and this entity loaned Sintx the 2.5m at 10% and warrants though Dr Bal's investment firm. Furthermore, this loan worked as a bridge to secure Sintx IP once Hercules loan was paid off as indicated in the above quote. This loan protected Sintx Core IP until about the time that CTL took over this role. If Zimmer Biomet is indeed a stakeholder as the evidence shows, it would certainly want to see Sintx IP protected from other entities. However for it to exert this sort of influence, it would need PERSONS connected to it that it could influence like Dr. Bal & Pezzotti and/or the institutions they are connected to.
Quote Sources
1. https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
2. https://www.sec.gov/Archives/edgar/data/1136869/000156459017016390/zbh-10q_20170630.htm pg 57
3. https://www.sec.gov/Archives/edgar/data/1136869/000156459018003549/zbh-10k_20171231.htm pg 55
4. https://www.sec.gov/Archives/edgar/data/1269026/000149315217008482/form8-k.htm
Could it be that there is a strategy to distract people away from looking at the basic data?
Is all this an exercise to create more and more forum verbiage to drown out any serious discussion of evidence?
Recent SINT News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2024 09:15:30 PM
- SINTX Technologies Secures Patent Allowance for Wide-Ranging Silicon Nitride Biomaterial Applications • GlobeNewswire Inc. • 12/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 09:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2024 06:15:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/26/2024 11:10:12 AM
- SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment • GlobeNewswire Inc. • 11/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2024 10:13:22 PM
- SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer • GlobeNewswire Inc. • 11/19/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2024 11:15:16 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/15/2024 12:25:52 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/14/2024 09:15:08 PM
- SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 • GlobeNewswire Inc. • 11/14/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 08:50:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 08:30:16 PM
- SINTX Announces Key Executive Promotions: Ryan Bock, PhD, Named Chief Technology Officer and Ann Kutsch Promoted to President of SINTX TA&T • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2024 08:30:31 PM
- Prodways and SINTX Announce Joint Webinar Stay Ahead of the Curve: “Innovations in Ceramic Manufacturing: The Role of 3D Printing” • GlobeNewswire Inc. • 09/20/2024 12:00:00 PM
- SINTX Announces Completion of $3.1 Million ATM Equity Public Offering • GlobeNewswire Inc. • 09/19/2024 12:00:00 PM
- Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9% • IH Market News • 09/10/2024 10:02:31 AM
- SINTX Receives Notice of Allowance for United States Patent Application for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Significant Cost Reductions, Extended Cash Runway, and Exploration of Strategic Partnerships • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:32:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 01:05:17 PM
- SINTX Technologies Announces Appointment of Eric K. Olson as Chief Executive Officer • GlobeNewswire Inc. • 08/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 08:45:11 PM
51 Labs Expands Sports Nutrition Line with Five New Innovative Products, Company in final phase of name and ticker symbol change • CAFI • Feb 10, 2025 9:00 AM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM
VAYK Project $700K 2024 Revenue with $150K Net Profit • VAYK • Feb 5, 2025 12:43 PM
UAV Corp (UMAV) Kicks Off Landmark "SKY" Hangar Project with Land Clearing at Costin Airport Setting Stage for Q1 2025 Groundbreaking • UMAV • Feb 5, 2025 8:30 AM
HealthLynked Corp. Releases Annual Shareholder Letter Highlighting Recent Product Development and Strategic Vision for the Future • HLYK • Feb 4, 2025 8:00 AM
Wytec Wins Multi-State Government Contract for AI Gunshot Detection • WYTC • Feb 3, 2025 7:16 AM